We are proud to recognize Dr. Larson Ode as a co-author of a groundbreaking clinical trial published last week in the New England Journal of Medicine. The study demonstrates the effectiveness of a novel treatment of acquired hypothalamic obesity, a rare and devastating condition that until now has lacked effective medical therapies. In the phase 3 trial, researchers evaluated setmelanotide in children and adults with hypothalamic obesity resulting from tumors, injuries, or other damage to the hypothalamic region of the brain. After 52 weeks of treatment, participants receiving setmelanotide experienced a 16.5% reduction in body mass index (BMI) on average, while those receiving placebo showed an increase in BMI. The findings represent an important breakthrough for patients and families affected by hypothalamic obesity, a condition that is notoriously difficult to treat because it disrupts the brain pathways that regulate appetite and energy balance. By targeting the key brain pathways involved, setmelanotide addresses the mechanisms underlying the disease rather than simply treating its symptoms. Published in one of the world’s leading medical journals, this study provides compelling evidence that setmelanotide may offer a much-needed therapeutic option for individuals living with acquired hypothalamic obesity. We congratulate Dr. Larson Ode and her co-authors on this significant achievement and on their contributions to advance care for patients with complex obesity disorders. The study’s abstract can be found at this PubMed link.
Dr. Larson Ode also contributed to a followup article published shortly after the above main article. The followup article describes the impact of setmelanotide on the participants’ energy levels, physical activity, and their perception of the impact of the medication on their quality of life. This very practical outcome measure is extremely important, arguably even more than the biological outcomes addressed in the original article. The reason is that hypothalamic obesity is associated with poor energy levels and substantial reductions in quality of life, beyond simple obesity. This study found meaningful improvements in perceived energy and activity levels in the majority of participants receiving setmelanotide but only in a very small fraction of those receiving placebo. It is important that this new therapy has the potential to improve quality of life in people who have acquired hypothalamic obesity. The study’s abstract can be found at this PubMed link.
